Clinical trials: Erythropoietin
Patients Receiving a Kidney From a Non-Heart-Beating Donor
PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation
Randomized, double blind, placebo controlled, prospective trial investigating the effect of erythropoietin in renal transplantation. The investigators postulate that erythropoietin reduces the risk of delayed graft function.
- Trial name
- NCT00157300
- Testing
- Epoetin beta
- Where
- 2 sites in Netherlands
- Volunteers
- 92 people
- Sponsor
- Leiden University Medical Center
Low and Int 1-risk Myelodysplastic Syndrome
Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.
The primary purpose of this trial was is to assess the effect of treatment with deferasirox combined with erythropoietin vs. erythropoietin alone on erythropoiesis in patients with low- and int-1-risk myelodysplastic syndrome.
- Trial name
- NCT01868477
- Testing
- Deferasirox DFX, DT, Erythropoietin alpha, Deferasirox DFX, FCT
- Where
- 30 sites in Algeria, Argentina and 8 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Renal Failure
EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure
The purpose of the study is to evaluate the effectiveness, safety and clinical outcome of Epoetin alfa with dosing regime in accordance with Summary of Product Characteristics in the treatment of anemia in predialysis.
- Trial name
- NCT00338000
- Testing
- Epoetin alfa
- Volunteers
- 292 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Chronic Hepatitis C
Use or Non-use of Epoetin Beta in Patients Infected by Chronic Hepatitis C
The purpose is to demonstrate a correction of anemia in hepatitis C virus treatment with peginterferon plus ribavirin.
- Trial name
- NCT00262379
- Testing
- epoetin beta (NeoRecormon®)
- Where
- 37 sites in France
- Volunteers
- 229 people
- Sponsor
- University Hospital, Angers
Anemia
Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)
Erythropoietin (EPO) is a hormone produced in the kidney. Its function is to stimulate the production of red cells in the bone marrow.
- Trial name
- NCT00091910
- Testing
- Epoetin alfa
- Volunteers
- 1,460 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Developmental Disabilities
Recombinant Human Erythropoietin Improve Neurodevelopmental Outcomes in Extremely Preterm Infants
In the ELGAN (Extremely Low Gestational Age Newborn) study, abnormal brain structure and function were associated with intermittent or sustained systemic inflammation (ISSI).
- Trial name
- EPO (NCT02745990)
- Testing
- Recombinant human erythropoietin, Normal saline
- Volunteers
- 440 people
- Sponsor
- Huiqing Sun
Type 1 Diabetes
Glucose Variability in Type 1 Diabetes and Its Effect on Factors That Influence New Vessel Formation
The aim of the study is to see how glycaemic control and glycaemic variability affect levels of HIF, VEGF, erythropoietin and cortisol in Paediatric Type 1 diabetics on insulin pump therapy.
- Trial name
- INDIGO 2 (NCT01429467)
- Testing
- Continuous Glucose Monitor (CGM) and Telemedicine (Enlite Guardian real-time system Medtronic®)
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- University of Dundee
Chronic Kidney Disease, Chronic Renal Failure
A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
The purpose of this study is to demonstrate therapeutic equivalence of IV Epoetin Hospira compared to IV Epogen (Amgen), based on maintenance of Hb levels and study drug dose requirements in patients treated for anemia associated…
- Trial name
- AiME - 01 (NCT01473407)
- Testing
- Epoetin Hospira, Epogen (Amgen)
- Where
- 85 sites in United States, Puerto Rico
- Volunteers
- 612 people
- Sponsor
- Pfizer
Beta-Thalassemia
Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia
OBJECTIVES: I. Determine whether arginine butyrate with or without epoetin alfa can stimulate gamma-globin chain production to a degree that decreases anemia and results in hematologic improvement in patients with thalassemia…
- Trial name
- NCT00006136
- Testing
- arginine butyrate, epoetin alfa
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Boston University
Pure Red-Cell Aplasia, Chronic Kidney Failure
Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney Failure
The purpose of this study is to estimate the incidence rate of pure red cell aplasia (PRCA; aplastic anemia) mediated by erythropoietin (EPO) antibodies in patients who are receiving subcutaneous (s.c.) epoetin alfa (polysorbate…
- Trial name
- PRIMS (NCT00391287)
- Where
- 387 sites in Australia, Belgium and 13 more
- Volunteers
- 15,334 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anemia
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies
This study will evaluate the efficacy, safety, and pharmacoeconomics of treatment with subcutaneous (SC) epoetin beta (NeoRecormon) in participants with hematologic malignancies or solid tumors.
- Trial name
- NCT02564094
- Testing
- Epoetin beta
- Where
- 9 sites in Bulgaria
- Volunteers
- 54 people
- Sponsor
- Hoffmann-La Roche
Anemia
A Study of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia.
This study will determine whether 8 weekly monitoring of hemoglobin and iron parameters in the correction phase of NeoRecormon therapy in patients with renal anemia is as safe and effective as 4 weekly monitoring.
- Trial name
- NCT00440063
- Testing
- epoetin beta [NeoRecormon]
- Where
- 9 sites in Australia
- Sponsor
- Hoffmann-La Roche
Infant, Premature, Leukomalacia, Periventricular
Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants
Periventricular leukomalacia (PVL) is one of the most common brain injuries that occur in preterm infants. Inflammation, hypoxia-ischemia, free oxygen radical formation and excitotoxicity are all known pathogenic mechanisms that…
- Conditions
- Infant, Premature, Leukomalacia, Periventricular, Intraventricular Hemorrhage, Retinopathy of Prematurity
- Trial name
- NCT00910234
- Testing
- recombinant human erythropoietin (rhEpo), Normal saline
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- China Medical University Hospital
Cerebral Palsy
Erythropoietin Therapy for Children With Cerebral Palsy: Phase 1
This purpose of this phase 1 study is to investigate the safety and efficacy of erythropoetin for children with cerebral palsy.
- Trial name
- NCT01586052
- Testing
- Erythropoietin
- Where
- South Korea
- Volunteers
- 11 people
- Sponsor
- MinYoung Kim, M.D.
Anemia
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia
This observational study will evaluate the use in clinical practice and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in stage III-IV chronic kidney disease patients not on dialysis receiving Mircera for the…
- Trial name
- NCT01695746
- Testing
- C.E.R.A.
- Where
- 6 sites in India
- Volunteers
- 108 people
- Sponsor
- Hoffmann-La Roche
Anemia, Critical Illness
Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.
The purpose of this study is to describe the pharmacokinetics (PK) of six different dosing regimens of epoetin alfa (PROCRIT®) in anemic critically ill subjects
- Trial name
- NCT00210756
- Testing
- epoetin alfa
- Volunteers
- 60 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pure Red-cell Aplasia
A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment
The purpose of this study is to investigate the relationship of anti-erythropoietin antibodies to the clinical course and outcome of pure red cell aplasia (PRCA) in participants currently or previously treated with recombinant…
- Trial name
- NCT00211042
- Testing
- No intervention
- Where
- 21 sites in Brazil, Canada and 6 more
- Volunteers
- 52 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anemia
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
This single arm study will assess the efficacy and safety of intravenous Mircera, administered with pre-filled syringes, for the treatment of anemia in patients with chronic kidney disease who are on dialysis, and who have…
- Trial name
- NCT00413894
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 105 sites in Germany
- Volunteers
- 424 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery
The study is investigating whether randomization to perioperative darbepoetin alfa treatment improves the rehabilitation following surgery for colonic and rectal cancer.
- Trial name
- NCT00122720
- Testing
- Darbepoetin Alfa
- Where
- 5 sites in Denmark
- Volunteers
- 200 people
- Sponsor
- Herning Hospital
Healthy
PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects.
The hypothesis of this trial is that the test drug (Eritromax ®) pharmacokinetics and pharmacodynamics parameters are similar to the comparator drug (Eprex ®) in healthy subjects following administration of multiple intravenous…
- Trial name
- NCT01664221
- Testing
- Epoetin Alfa
- Where
- Brazil
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil